These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38278469)

  • 1. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
    Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
    Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Molenaar RJ; Radivoyevitch T; Nagata Y; Khurshed M; Przychodzen B; Makishima H; Xu M; Bleeker FE; Wilmink JW; Carraway HE; Mukherjee S; Sekeres MA; van Noorden CJF; Maciejewski JP
    Clin Cancer Res; 2018 Apr; 24(7):1705-1715. PubMed ID: 29339439
    [No Abstract]   [Full Text] [Related]  

  • 3. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Drp1-regulated changes in T cell activity on the combined antitumor effects of PARPi and PD-1 inhibitors.
    Ma J; Song J; Yi X; Zhang S; Huang L; Sun L; Gao R; Han C
    Int Immunopharmacol; 2024 May; 132():112006. PubMed ID: 38581995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK Inhibition Remodels the Immune Landscape of Mutant
    Yang B; Li X; Fu Y; Guo E; Ye Y; Li F; Liu S; Xiao R; Liu C; Lu F; Huang J; Qin T; Han L; Peng G; Mills GB; Sun C; Chen G
    Cancer Res; 2021 May; 81(10):2714-2729. PubMed ID: 33589518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 7. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer.
    Shen D; Luo J; Chen L; Ma W; Mao X; Zhang Y; Zheng J; Wang Y; Wan J; Wang S; Ouyang J; Yi H; Liu D; Huang W; Zhang W; Liu Z; McLeod HL; He Y
    Cancer Lett; 2022 Dec; 550():215919. PubMed ID: 36116741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.
    Yi XF; Gao RL; Sun L; Wu ZX; Zhang SL; Huang LT; Han CB; Ma JT
    Biomed Pharmacother; 2023 Jul; 163():114770. PubMed ID: 37105074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.
    Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y
    Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation in Combination with Immune Checkpoint Blockade and DNA Damage Response Inhibitors in Mice: Dosage Optimization in MC38 Syngeneic Tumors via Modelling and Simulation.
    Hodson D; Mistry H; Yates J; Farrington P; Staniszewska A; Guzzetti S; Davies M; Aarons L; Ogungbenro K
    J Pharmacol Exp Ther; 2023 Oct; 387(1):44-54. PubMed ID: 37348964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer.
    Chang J; Quan S; Tian S; Wang S; Li S; Guo Y; Yang T; Yang X
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):304. PubMed ID: 38869633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
    Zhang N; Gao Y; Huang Z; Dai P; Luo Y; Wu Q; Jiang X; Sun W; Zhang J; Han L; Zhang J; Gong Y; Xie C
    Cancer Lett; 2022 Oct; 545():215852. PubMed ID: 35926817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
    Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
    J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
    Gbyli R; Song Y; Liu W; Gao Y; Biancon G; Chandhok NS; Wang X; Fu X; Patel A; Sundaram R; Tebaldi T; Mamillapalli P; Zeidan AM; Flavell RA; Prebet T; Bindra RS; Halene S
    Leukemia; 2022 May; 36(5):1313-1323. PubMed ID: 35273342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers.
    Shapiro GI; Barry SM
    Cancer Treat Res; 2023; 186():207-221. PubMed ID: 37978138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor-Induced Growth Suppression.
    Geng C; Zhang MC; Manyam GC; Vykoukal JV; Fahrmann JF; Peng S; Wu C; Park S; Kondraganti S; Wang D; Robinson BD; Loda M; Barbieri CE; Yap TA; Corn PG; Hanash S; Broom BM; Pilié PG; Thompson TC
    Clin Cancer Res; 2023 Nov; 29(21):4464-4478. PubMed ID: 37581614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    Rabenau K; Hofstatter E
    Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.